Study wrapper · #1210
Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes.
Editor's note
The evidence base here is thin — a systematic search across four databases surfaced only 13 published cases — so this reads as a signal to watch rather than a measured risk rate. Still, the pattern is internally consistent: onset clustering after rapid dose escalation, and full reversal once the drug was withdrawn. For a drug class whose mechanism includes delayed gastric emptying, the finding is mechanistically unsurprising, and it reinforces the standard guidance on slow titration and follow-up of persistent GI symptoms.
Plain-language abstract
Researchers systematically pooled 12 published case reports covering 13 people who developed gastroparesis — a condition where the stomach empties too slowly — while taking GLP-1 drugs, with semaglutide the most frequently implicated agent. Symptoms such as nausea, vomiting, bloating, and early fullness often appeared after a dose increase or an inappropriate restart, and in every reported case they resolved after the drug was stopped. The authors advise gradual dose titration and attention to stomach symptoms that do not settle.